Brief: Arovella Therapeutics Updates On Ala-101 And Oncarlytics Research Collaboration

Arovella Therapeutics

04/12/2023 24:59

Dec 4 (Reuters) - Arovella Therapeutics Ltd  ALA.AX :
    * UPDATE ON ALA-101 AND ONCARLYTICS RESEARCH COLLABORATION
    * AVAILABILITY OF PRELIMINARY IN VIVO DATA FOR STUDY DELAYED
DUE
TO TECHNICAL CHALLENGES
    * DELAY DOES NOT IMPACT PROGRESS OF ALA‐101 TOWARDS FIRST IN
HUMAN
CLINICAL TRIALS
    * CONTINUES TO COMPLETE MANUFACTURING OPTIMISATION AND
SCALE‐UP
FOR ALA‐101

Source text for Eikon:  ID:nASX2V0kC8 
Further company coverage:  ALA.AX 

 ((Reuters.Briefs@thomsonreuters.com;))